In physiological hemostasis a prompt recruitment of platelets on the vessel damage prevents
the bleeding by the rapid formation of a platelet plug. Qualitative and/or quantitative platelet …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Background Patients' responses to oral antiplatelet therapy are subject to variation. Bedside
monitoring offers the opportunity to improve outcomes after coronary stenting by …

Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of
treatment to prevent thrombotic complications of acute coronary syndromes and …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Background—Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist. This is
the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using …

Point-of-care (POC) assays are available for a variety of coagulation tests. These assays are
generally simple to perform and have a more rapid turnaround time than their central …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Background Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet
regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent …